Leap Therapeutics (NASDAQ:LPTX) Stock Rating Lowered by Robert W. Baird

Leap Therapeutics (NASDAQ:LPTX) was downgraded by equities research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday,Briefing.com Automated Import reports. They presently have a $1.25 price objective on the stock, down from their previous price objective of $9.00. Robert W. Baird’s price target indicates a potential upside of 92.31% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.50 price target on shares of Leap Therapeutics in a report on Thursday, January 16th.

Leap Therapeutics Price Performance

Shares of NASDAQ LPTX opened at $0.65 on Wednesday. The company has a 50 day simple moving average of $2.86 and a 200 day simple moving average of $2.77. Leap Therapeutics has a 1 year low of $0.62 and a 1 year high of $4.79. The firm has a market cap of $24.91 million, a PE ratio of -0.34 and a beta of 0.17.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Key Client Fiduciary Advisors LLC increased its position in shares of Leap Therapeutics by 12.2% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after buying an additional 39,330 shares during the period. HB Wealth Management LLC grew its holdings in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after acquiring an additional 26,150 shares during the period. Exome Asset Management LLC bought a new position in shares of Leap Therapeutics in the 3rd quarter worth about $264,000. Geode Capital Management LLC lifted its stake in shares of Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after purchasing an additional 50,194 shares during the period. Finally, HighTower Advisors LLC bought a new stake in shares of Leap Therapeutics during the 3rd quarter valued at about $65,000. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.